CDEK
← All drugs Report issue

scopolamine

Trade name: transderm scop

Small moleculeapproved

Approved

Dec 31, 1979

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function. Scopolamine is used for premedication in anesthesia and for the prevention of nausea and vomiting (post operative and associated with motion sickness). — NCATS

Clinical trial activity

105 trials · 86 clinical orgs · 11 marketing orgs

Phase 1
26
Phase 2
34
Phase 3
19
Phase 4
24

Earliest trial started Jan 1, 1996 (NCT00152724)

Timeline

1900s

  1. Jun 1, 1900

    Evidence of US Marketing

1970s

  1. Dec 31, 1979

    GlaxoSmithKline — Earliest FDA Approval

  2. Dec 31, 1979

    GlaxoSmithKline — NDA Secondary Org

  3. Dec 31, 1979

    Baxalta — Marketing Organization

  4. Dec 31, 1979

    GlaxoSmithKline — NDA Organization

  5. Dec 31, 1979

    Baxalta — NDA Secondary Org

1990s

  1. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 30, 2015

    Padagis Us — Marketing Organization

  2. Jan 30, 2015

    Perrigo — Marketing Organization

  3. Jun 19, 2019

    Mylan — Marketing Organization

2020s

  1. Nov 24, 2020

    RiconPharma — Marketing Organization

  2. Jan 10, 2022

    Actavis — Marketing Organization

  3. Jan 10, 2022

    AbbVie — Marketing Organization

  4. May 6, 2024

    Rhodes Pharmaceuticals, L.P. — Marketing Organization

  5. Aug 29, 2024

    Zydus Discovery DMCC — Marketing Organization

  6. Jun 9, 2025

    Amneal Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 31, 1979
  • approvedJun 1, 1900

Chemistry & pharmacology

Loading structure…

SMILES

CN1[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4
Mol. weight
303.3529 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (1s,3s,5r,6r,7s)-6,7-epoxytropan-3-yl (2s)-3-hydroxy-2-phenylpropanoate
  • (1s,3s,5r,6r,7s)-6,7-epoxytropan-3-yl (2s)-3-hydroxy-2-phenylpropanoate
  • 6,7-epoxytropine tropate
  • 6,7-epoxytropine tropate
  • 6-beta,7-beta-epoxy-3-alpha-tropanyl s-(-)-tropate
  • 6-beta,7-beta-epoxy-3-alpha-tropanyl s-(-)-tropate
  • [7(s)-(1α,2β,4β,5α,7β)]-9-butyl-7-(3-hydroxy- 1-oxo-2-phenylpropoxy)-9-methyl-3-oxa- 9-azonitricyclo[3.3.1.0(2,4)]nonane
  • [7(s)-(1α,2β,4β,5α,7β)]-9-butyl-7-(3-hydroxy- 1-oxo-2-phenylpropoxy)-9-methyl-3-oxa- 9-azonitricyclo[3.3.1.0(2,4)]nonane
  • alpha-(hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
  • alpha-(hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester
  • buscapine
  • buscopan
  • buscopan
  • buscopan
  • buscopan
  • buscopan
  • buscopan
  • butylhyoscine
  • butylhyoscine
  • butylscopolamine
  • butylscopolamine
  • butylscopolamine
  • butylscopolamine
  • butylscopolaminebromide
  • butylscopolaminebromide
  • butylscopolamine bromide
  • butylscopolamine bromide
  • butylscopolamine bromide
  • butylscopolamine bromide
  • butylscopolammonium
  • hyoscine
  • hyoscine
  • hyoscine
  • hyoscine
  • hyoscine
  • (-)-hyoscine
  • (-)-hyoscine
  • hyoscine bromide
  • hyoscine bromide
  • hyoscine butylbromide
  • hyoscine butylbromide
  • hyoscine butylbromide
  • hyoscine butylbromide
  • hyoscine butyl bromide
  • hyoscine butyl bromide
  • hyoscine hydrobromide
  • hyoscine hydrobromide
  • isopto hyoscine
  • isopto hyoscine
  • isoptpo hyoscine
  • isoptpo hyoscine
  • joy-rides
  • levo-duboisine
  • n-butylscopolammonium bromide
  • n-butylscopolammonium bromide
  • omnopon-scopolamine
  • omnopon-scopolamine
  • omnopon-scopolamine
  • papaveretum-hyoscine
  • sc401b
  • scopalamine
  • scopalamine
  • scopine (-)-tropate
  • scopine (-)-tropate
  • scopine (−)-tropate
  • scopine (−)-tropate
  • scopoderm
  • scopoderm
  • scopoderm
  • scopoderm tts
  • scopoderm tts
  • scopola
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • scopolamine
  • (-)-scopolamine
  • (-)-scopolamine
  • scopolamine bromobutylate
  • scopolamine bromobutylate
  • scopolamine butylbromide
  • scopolamine butylbromide
  • scopolamine butylbromide
  • scopolamine butylbromide
  • scopolamine butylbromide
  • scopolamine butyl hydroxide
  • scopolamine hcl
  • scopolamine hydrobromide
  • scopolamine hydrobromide
  • scopolamine hydrobromide
  • scopolamine hydrobromide
  • scopolamine hydrobromide
  • scopolamine hydrochloride
  • (-)-scopolamine,n-butyl-, bromide
  • scopolamine n-butylbromide
  • scopolamine n-butylbromide
  • transcop
  • transcop
  • transderm
  • transderm
  • transderm-scop
  • transderm-scop

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07271303N/ADec 1, 2025Jiao Tong University
NCT06398054Phase 4Oct 1, 2024Government of Italy
NCT06014385Phase 1Jan 31, 2024Janssen Pharmaceutica NV, Yale University
NCT05640232Phase 3Sep 30, 2023EMS S/A
NCT06056869N/ASep 27, 2023Ain Shams University
NCT05715398Phase 1/Phase 2 (Phase 2)Feb 28, 2023Government of China, Jiao Tong University
NCT06207539Early Phase 1 (Phase 1)Dec 1, 2022Ain Shams University
NCT05505877Phase 1/Phase 2 (Phase 2)Sep 10, 2022Government of China, Sun Yat-Sen University
NCT04999449Phase 1Aug 31, 2022Dartmouth University
NCT05548270Phase 3Aug 23, 2022Defender Pharmaceuticals, Inc., Repurposed Therapeutics, Inc.
NCT05886660Phase 2Jan 21, 2022NASA, Repurposed Therapeutics, Inc.
NCT04666701Phase 2Nov 30, 2021EMS S/A
NCT04785118Phase 4Oct 1, 2021Assiut University
NCT05852730Phase 2Aug 10, 2021NASA, Repurposed Therapeutics, Inc.
NCT04891653Phase 1Jun 30, 2021Qingfeng Pharmaceutical Group
NCT04947423Phase 3Jun 14, 2021Defender Pharmaceuticals, Inc., Repurposed Therapeutics, Inc.
NCT04866355N/AFeb 28, 2021Universidad de Alcala, Madrid
NCT04682860Phase 4Dec 31, 2020Ankara Yildirim Beyazıt University
NCT06927817Phase 4Nov 15, 2020Saglik Bilimleri Universitesi
NCT04391361Phase 2Jun 1, 2020Jiao Tong University
Showing 20 of 105 trials
Page 1 / 6

Organizations

Research & Development (86)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Repurposed Therapeutics, Inc.For profit111132014
Boehringer IngelheimFor profit8831998
Assiut UniversityAcademic/Hospital7732015
Cairo UniversityAcademic/Hospital5522016
Ain Shams UniversityAcademic/Hospital4442014
Harvard UniversityAcademic/Hospital3322008
Jiao Tong UniversityAcademic/Hospital3222020
MerckFor profit3122007
Defender Pharmaceuticals, Inc.For profit2012021
Drexel UniversityAcademic/Hospital2212008
EMS S/AFor profit2222021
Government of ChinaGovernment2212022
NASAGovernment2012021
National Institute of Mental Health (NIMH)Government2222003
PfizerFor profit2212011
Seoul National UniversityAcademic/Hospital2222007
United States NavyGovernment2112014
Yale UniversityAcademic/Hospital2212020
Ankara Yildirim Beyazıt UniversityAcademic/Hospital1112020
AstraZenecaFor profit1112014
86 organizations
Page 1 / 5

Marketing (14)

OrganizationOrg typeRelationshipDate
AbbVieFor profitMKTGJan 10, 2022
ActavisFor profitMKTGJan 10, 2022
Amneal PharmaceuticalsFor profitMKTGJun 9, 2025
Amneal PharmaceuticalsFor profitSYNJun 9, 2025
BaxaltaFor profitMKTGDec 31, 1979
BaxaltaFor profitNDA2Dec 31, 1979
GlaxoSmithKlineFor profitNDA2Dec 31, 1979
GlaxoSmithKlineFor profitNDADec 31, 1979
MylanFor profitMKTGJun 19, 2019
Padagis UsFor profitMKTGJan 30, 2015
PerrigoFor profitMKTGJan 30, 2015
Rhodes Pharmaceuticals, L.P.For profitMKTGMay 6, 2024
RiconPharmaFor profitMKTGNov 24, 2020
Zydus Discovery DMCCFor profitMKTGAug 29, 2024